Can-Fite CEO to Present Namodenoson Efficacy in Liver Cancer as Expert Speaker at Targeted Adenosine Cancer Immunotherapy Summit

  • Namodenoson induced a complete response and eliminated all cancerous lesions in a patient with advanced liver cancer in a phase II study

  • Pivotal Phase III trial for treatment of liver cancer now open for patient recruitment

PETACH TIKVA, Israel, May 02, 2022–(BUSINESS WIRE)–Can-Fite BioPharma Ltd.. (NYSE American: CANF) (TASE: CFBI), a biotechnology company developing a pipeline of proprietary small molecule drugs that treat inflammatory diseases, cancer and the liver, today announced that the company’s CEO, Dr. Pnina Fishman, was invited as an expert speaker to deliver a presentation titled “Targeting the A3 Adenosine Receptor for the Treatment of Advanced Liver Cancer” at the Adenosine Pathway Targeted Cancer Immunotherapy Summit in Boston on May 12, 2022.

This press release is multimedia. See the full version here:

Radiological data show disappearance of tumor lesions in a patient treated with Namodenoson who had advanced disease and was completely cured. (Graphic: Business Wire)

Namodenoson, a small, orally bioavailable drug that specifically binds to the A3 adenosine receptor (A3AR), overexpressed in liver cancer but not in normal cells, is heading for a pivotal phase III trial in liver cancer liver. The trial has received the green light from the US FDA and the European Medicines Agency (EMA) and is now open to enroll approximately 450 patients diagnosed with hepatocellular carcinoma (HCC) and Child Pugh B7 (CPB7) that have not responded to other approved therapies. A patient from the previous phase II HCC study who continues to be treated with Namodenoson survived more than five years and cleared all cancerous lesions.

“Adenosine pathway targets have become one of the most clinically validated pathways in oncology, further validating our A3AR target for the treatment of liver and other cancers. I am delighted to be invited to speak and share Can-Fite’s experience in developing drugs for the adenosine pathway and the clinical trials and radiology data showing disappearance of a patient’s tumor lesions treated with Namodenoson who had advanced disease and made a full recovery,” said Can-Fite CEO Dr. Pnina Fishman.

Inaugural adenosine-targeted cancer immunotherapy Summit is dedicated to optimizing the efficacy of drugs targeting the adenosine pathway, overcoming the challenges of resistance and immunosuppression, and energizing therapeutics in the clinic. The conference aims to maximize the clinical and commercial opportunity of the adenosine pathway as a second-generation immuno-oncology target.

About Namodenoson

Namodenoson is a small, orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson has been evaluated in phase II trials for two indications, as a second-line treatment for hepatocellular carcinoma and as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly expressed in diseased cells while low expression is found in normal cells. This differential effect explains the excellent safety profile of the drug.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is a late-stage clinical-stage drug development company with a technology platform designed to address multi-billion dollar markets in the treatment of cancer, liver and inflammatory diseases. . The company’s lead drug candidate, Piclidenoson, has completed enrollment in a Phase III trial for psoriasis. Can-Fite’s liver drug Namodenoson is being evaluated in a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH), with enrollment expected to begin in a Phase III trial for carcinoma hepatocellular (HCC), the most common form of liver cancer. Namodenoson has received orphan drug designation in the United States and Europe and Fast Track designation as a second-line treatment for HCC by the United States Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers, including colon, prostate and melanoma. CF602, the Company’s third drug candidate, has demonstrated its efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information, please visit:

Forward-looking statements

This press release may contain forward-looking statements about Can-Fite’s expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results operations, strategies or prospects. Additionally, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, either orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should” or “anticipate” or their negatives or other variations of these words or other comparable words or that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included, but not limited to, in various documents filed by Can-Fite with the United States Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite’s authorized officers. officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements address matters that have not yet occurred, such statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual operations or results to differ materially from the operations and results anticipated in these forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to: our history of losses and our need for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or not at all; cash flow uncertainties and the inability to meet working capital requirements; the impact of the COVID-19 pandemic; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other business collaborations; the implementation of our business model and strategic plans for our businesses and product candidates; the extent of protection we are able to establish and maintain for the intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive businesses, technologies and our industry; statements regarding the impact of the political and security situation in Israel on our business; and the risks and other risk factors detailed in Can-Fite’s filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values ​​are highly volatile and may be affected by economic and other factors beyond its control. Can-Fite undertakes no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

See the source version on


Can-Fite BioPharma
Motti Farbstein
[email protected]

Comments are closed.